Millennium Management
ACHL

Millennium Management’s Achilles Therapeutics ACHL Stock Holding History

Millennium Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,117
Closed -$23.9K – 6674
2024
Q1 		$23.9K Sell
19,117
-11,832
-38% -$12.8K ﹤0.01% 5799
2023
Q4 		$27.5K Buy
30,949
+14,671
+90% +$12.6K ﹤0.01% 5587
2023
Q3 		$14.8K Sell
16,278
-22,091
-58% -$21K ﹤0.01% 5702
2023
Q2 		$36.3K Sell
38,369
-88,880
-70% -$84.4K ﹤0.01% 5536
2023
Q1 		$122K Buy
127,249
+45,494
+56% +$49.3K ﹤0.01% 5352
2022
Q4 		$74K Buy
+81,755
New +$138K ﹤0.01% 5672
2022
Q1 		– Sell
-26,423
Closed -$132K – 7625
2021
Q4 		$132K Sell
26,423
-119,106
-82% -$721K ﹤0.01% 6137
2021
Q3 		$1.13M Sell
145,529
-50,615
-26% -$333K ﹤0.01% 4536
2021
Q2 		$1.92M Sell
196,144
-6,641
-3% -$90K ﹤0.01% 4007
2021
Q1 		$3.36M Buy
+202,785
New +$3.36M ﹤0.01% 3018

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Millennium Management's ACHL Position: Q2 2024 in Review

Millennium Management sold out of Achilles Therapeutics (ACHL) in Q2 2024, closing a stake of 19,117 shares — an estimated $23.9K sold.

Millennium Management first reported a position in ACHL in Q1 2021 and held it in 10 quarters. The position peaked at $3.36M in Q1 2021. 27 funds tracked by Wall St. Rank hold ACHL as of Q2 2024.

  • Millennium Management reported no remaining Achilles Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Millennium Management sold 19,117 Achilles Therapeutics shares in Q2 2024, an estimated $23.9K.
  • Millennium Management first reported a position in Achilles Therapeutics in Q1 2021 and held it in 10 quarters.
  • Millennium Management's Achilles Therapeutics position peaked at $3.36M in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.